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Abstract
Background: To estimate the incidence of complications, life expectancy and diabetes related mortality in the
Mexican diabetic population over the next two decades using data from a nation-wide, population based survey
and the United Kingdom Prospective Diabetes Study (UKPDS) outcome model
Methods: The cohort included all patients with type 2 diabetes evaluated during the National Health and Nutrition
Survey (ENSANut) 2006. ENSANut is a probabilistic multistage stratified survey whose aim was to measure the
prevalence of chronic diseases. A total of 47,152 households were visited. Results are shown stratified by gender,
time since diagnosis (> or ≤ to 10 years) and age at the time of diagnosis (> or ≤ 40 years).
Results: The prevalence of diabetes in our cohort was 14.4%. The predicted 20 year-incidence for chronic
complications per 1000 individuals are: ischemic heart disease 112, myocardial infarction 260, heart failure 113,
stroke 101, and amputation 62. Furthermore, 539 per 1000 patients will have a diabetes-related premature death.
The average life expectancy for the diabetic population is 10.9 years (95%CI 10.7-11.2); this decreases to 8.3 years
after adjusting for quality of life (CI95% 8.1-8.5). Male sex and cases diagnosed after age 40 have the highest risk
for developing at least one major complication during the next 20 years.
Conclusions: Based on the current clinical profile of Mexican patients with diabetes, the burden of disease related
complications will be tremendous over the next two decades.
Background
Diabetes is the principal cause of death in Mexico [1]. Its
prevalence in adults over the age of 20 has grown from
6.7% in 1993 to nearly 14% in 2006 [2-4]. Nationwide
population based surveys providing unbiased information
regarding the prevalence and clinical characteristics of
persons with diabetes are scant [5,6]. In Mexico, three
nationwide surveys have shown that adults with type 2
diabetes have a high prevalence of co-morbid conditions
which contribute to the high incidence of macrovascular
and microvascular complications. Regrettably, the inci-
dence of chronic complications is unknown.
Simulation modeling is gaining acceptance as a valu-
able tool for providing long-term information regarding
prognosis; such information is often unavailable from
clinical studies. Several simulation models [7-12] are
available for estimating the incidence of diabetic compli-
cations. The United Kingdom Prospective Diabetes
Study (UKPDS) outcome model is the most popular.
This model was developed using data obtained from
patients who participated in the UKPDS. In this study
the medical history, biochemical variables and diabetes
related complications were documented in the vast
majority of patients, with very few patients lost during
follow-up [13,14].
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representative data have not been published in Latin
American countries, the objective of this report is to
estimate the incidence of complications, life expectancy,
quality-adjusted life expectancy and diabetes related
mortality in the Mexican diabetic population over the
next two decades. This will allow us to simulate the
challenges that the Mexican health system will face in
the next 20 years.
Materials and methods
Population sample
The 2006 National Health and Nutrition Survey (ENSA-
Nut) was a cross sectional study including individuals
representative of those living in Metropolitan, urban and
rural areas. A multistage, stratified and probabilistic
sampling procedure was used to collect information. A
random sample of Basic Geographical Statistical Units
was obtained in all states of Mexico, and neighborhood
blocks were randomly selected. In every home, a ran-
domly selected adult, adolescent, child and health ser-
vice user were invited to participate. A target of 4731
individuals and 1476 households was estimated per
state. The total number of households visited was
48600. A sample of this size is capable of detecting risk
factors that have a state-wide prevalence of at least 8.1%
with a relative error of estimation of 0.25, a design effect
o f1 . 7a n dan o n - r e s p o n s er a t eo f2 0 % .T h es t u d yw a s
carried out in accordance with the Helsinki Declaration
of Human Studies. Informed consent was obtained from
each participant. A separate consent form was signed by
participants who provided blood samples. The study was
approved by the Research and Ethics committees of the
Instituto Nacional de Salud Pública.
Methods
The procedures of the study are reported in detail else-
were [15,16]. Briefly, a structured interview was con-
ducted and a previously standardized questionnaire was
used to obtain demographic, socioeconomic, family
health history, past medical history and lifestyle infor-
mation (e.g. smoking). Diabetes was considered present
if subjects referred to a previous diagnosis or if the fast-
ing plasma glucose was ≥ 126 mg/dl [14]. Type 1 dia-
betes was diagnosed if insulin treatment was required
during the first two months after the diagnosis or if the
patient had history of ketoacidosis. Fasting blood sam-
ples were obtained in approximately 30% of the adult
population (n = 6613). These cases were randomly dis-
tributed among study subjects. This subsample has a
statistical power to detect conditions with a nation-wide
prevalence ≥ 8%. The response rate was 85%. Detailed
information about the methods used for the collection
of the data is published elsewhere [15]. The socio-
demographic parameters (age, gender, socioeconomic
status and body mass index) of the subsample were not
different from the rest of the population. The sampling
procedure was standardized during a two week training
course. The subjects were sampled at their homes; they
remained seated for five minutes before the blood sam-
ple was drawn. All analytical measurements were carried
out in the laboratories of the Instituto Nacional de
Salud Pública using commercial reagents described in
detail elsewere [15].
Simulation model
The United Kingdom Prospective Diabetes (UKPDS)
outcome model was used to estimate life expectancy,
quality-adjusted life years (QALY), risk for the develop-
ment of fatal and non fatal myocardial infarction,
ischemic heart disease, cerebrovascular event, cardiac
failure, amputation and death in the diabetic population.
The model was developed based on observations and
follow up over 10 years of 5102 patients with newly
diagnosed type 2 diabetes. It considers four risk factors
(HbA1c, HDL-cholesterol, total cholesterol, systolic
blood pressure and smoking) as longitudinal data and
adjusts a model of random effects to estimate the pat-
tern over time. Equations for HbA1c, systolic blood
pressure, total cholesterol and HDL-cholesterol are
based on annual changes of each risk factor, while
change in smoking habit is calculated in three-year time
periods from the diagnosis of diabetes. With respect to
diabetic complications, Weibull proportional risks
regression model was used to estimate occurrence of a
compound result for fatal and non-fatal events. In this
simulation model, ischemic heart disease and congestive
heath failure events are registered only if they occurred
prior to a myocardial infarction event. Separate equa-
tions were used to model diabetes and diabetes related
mortality using a combination of Gompertz regression
equations and logistic regression models. The impact of
different complications was obtained through the EQ-
5D health condition questionnaire given to patients free
of complications. It is assumed that multiple complica-
tions have an additive effect on quality of life. The simu-
lations are carried out in annual cycles. A combination
of bootstrap methods and multiple attribution were
used to handle uncertainty, such that confidence inter-
vals reflect uncertainty of the parameter in the model
[14]. Missing data were attributed considering the mean
values of the conditions according to age (< 40, 40-60
and > 60 years), gender and time of diagnosis (< 10 and
> 10 years). A license was obtained for the use of the
UKPDS outcome model (Serial 1896, July 21,2005). The
UKPDS Results Model version 1.1 was run with 1000
Monte Carlo essays per subject and with 10 re-sam-
plings (bootstraps) to handle uncertainty. It was
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time. The model’s three ethnic groups do not include
the Mexican population, therefore, the group most clo-
sely related to our study population was selected (Asian
Indians). Native American and Asian populations share
peculiarities in their body composition. In these popula-
tions, the mean body mass index (BMI) and height are
lower than that observed for Caucasians, although the
tendency towards abdominal obesity may be greater
[17,18]. Life expectancy, quality-adjusted life expectancy,
expected incidence of chronic complications were calcu-
lated for a 20 year period. Results are presented by gen-
der, time of diagnosis (> or ≤ to 10 years) and age of
diagnosis (> or ≤ 40 years).
Validation of the UKPDS outcome model for
cardiovascular (CVD) events in Mexicans
The UKPDS outcome model has not been applied pre-
viously in Mexicans. As a consequence, we run a sepa-
rate study to validate the estimates. For this purpose, a
retrospective study based on the medical charts of
patients with type 2 diabetes treated for at least 10 years
at the Instituto Nacional de Ciencias Médicas y Nutri-
ción was performed. Patients lost to follow up for more
than one year were excluded. Predicted (using baseline
variables at diagnosis) and observed proportions of pri-
mary cardiovascular events were compared. The discri-
mination (c-statistic) and calibration (Hosmer-
Lemeshow c
2) of the UKPDS outcome model were cal-
culated. A total of 1089 records were reviewed. Of these
654 records were excluded for the following reasons: 35
patients with type 1 diabetes mellitus, 13 patients with
secondary diabetes, 379 without HbA1c results, 42 with-
out a lipid profile, 2 patients were younger than age 20
at the time of diagnosis and 182 patients had cardiovas-
cular disease diagnosed in the initial visit. Thus, the
study sample was composed of 436 patients (217 men
and 219 women). The mean age at diagnosis of diabetes
was 48.7 years. One hundred and one (23.1%) died dur-
ing the follow-up period. Cardiovascular disease was the
cause of death in 52 patients (51.4%). In addition, 260
cardiovascular events were recorded (coronary events =
45, stroke = 45). Discrimination of the UKPDS outcome
model for CVD events was 0.66 (IC 95% 0.59-0.72). The
calibration was poor (Hosmer-Lemeshow c
2 =2 3 . 8 ,p=
0.03), but of the same magnitude as that reported by
Guzder [14]. The sensitivity and specificity for an esti-
mated 10-year CVD risk of 20% was 89% and 36%,
respectively.
Results
There were 6613 subjects in our study over the age of
20, representing 56,745,719 Mexicans. Seven percent of
the subjects had previous knowledge of their diabetic
condition. However, on analysis of biological samples,
the actual prevalence of diabetes was 14.4%. All cases
were considered as having type 2 diabetes; no case with
type 1 diabetes was identified. If we extrapolate this fig-
ure to the general population, the actual number of
Mexicans with diabetes is 7,316,950. The clinical charac-
teristics of the diabetic population are shown in Table 1.
Twenty year incidence of macrovascular complications
We estimate that 112 (95% CI 84-140) per 1000 persons
with diabetes will present at least one ischemic heart
disease event, corresponding to 882,433 calculated
events (95% CI 661,744-1,103,123). In addition, we esti-
mate that 113 (95% CI 65-161) per 1000 persons with
diabetes will develop a heart failure event, resulting in
889,443 new events (95% CI 509,638-1,269,248). With
respect to myocardial infarction, we calculate that 260
(95% CI 215-304) per 1000 diabetic patients will develop
this condition. This would correspond to 2,048,996 (95%
CI 1,699,743-2,398,248) new cardiovascular events. With
respect to the incidence of cerebral vascular disease, we
estimate that 101 (95% CI 69-133) per 1000 persons
with diabetes will have this type of complication
(798,188 new cases (95% CI 544,809-1,051,568)). Finally,
62 (95% CI 40-85) per 1000 persons with diabetes will
present an amputation; corresponding to 491,236 (95%
CI 313,900-668,572) amputations. These predicted inci-
dences are presented in Table 2.
Table 1 Description of the diabetic population included
in the Encuesta Nacional de Salud y Nutrición 2006
Population of 20 years or older n = 56,745,719
Diabetic population
Previously diagnosed 3,138,720 (7.0)
Diagnosed during the survey 4,178,230 (7.4%)
Total 7,316,950 (14.4)
Time from diagnosis (years) 0.5(0-7)
Age (years) 52 (42-62)
Men 51(41-60)
Women 53 (42-64)
Weight(kg) 71.6 (64-80.8)
Height (m) 1.57 (1.5-1.63)
Total Cholesterol (mmol/l) 5.22 (5.14-5.29)
HDL cholesterol (mmol/l) 1.02 (1.01-1.03)
Systolic blood pressure (mmHg.) 130 (120-140)
HbA1c (%) 11.4 (10.15-11.8)
Smoking
Never 5,395,934 (68.4)
Past 1,174,763(14.9)
Currently 1,322,280(16.8)
Data are shown either as median (interquartile range) or number (%)
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Simulated years Accumulated probability Number of expected cases/1000 diabetics Confidence Interval
95%
Total expected cases (CI95%)
Ischaemic heart disease
1 0.009 9 7 12 73,482
(52,026-94,939)
5 0.039 39 29 49 311,146
(232,355-389,936)
10 0.069 69 53 86 547,679
(415,306-680,052)
15 0.094 93 71 116 738,373
(557,617-919,129)
20 0.112 112 84 140 882,433
(661,744-1,103,123)
Myocardial infarction
1 0.019 20 13 26 155,025
(102,215-207,836)
5 0.088 88 67 109 695,535
(526,932-864,139)
10 0.159 159 128 191 1,258,903
(1,010,065-1,507,742)
15 0.216 217 178 255 1,710,383
(1,405,667-2,015,099)
20 0.259 260 215 304 2,048,996
(1,699,743-2,398,248)
Heart failure
1 0.010 10 5 16 81,640
(35,674-127,607)
5 0.039 40 22 57 311,887
(177,573-446-201)
10 0.069 70 41 98 551,131
(325,182-777,081)
15 0.094 94 55 133 742,646
(434,411-1,050,081)
20 0.112 113 65 161 889,443
(509,638-1,269-248)
Cerebrovascular disease
1 0.008 9 4 13 68,070
(35,505-100,636)
5 0.035 36 24 48 282,893
(186,677-379,110)
10 0.063 63 44 82 498,794
(348,475-649,112)
15 0.085 85 59 111 671,080
(469,221-872,938)
20 0.101 101 69 133 798,188
(544,809-1,051,568)
Amputation
1 0.006 7 2 11 51,666
(16,656-86,676)
5 0.021 22 12 31 170,582
(94,289-246,875)
10 0.036 36 23 49 282,205
(179,425-384,985)
15 0.049 49 32 66 389,413
(255,649-523,177)
20 0.062 62 40 85 491,236
(313,900-668,572)
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studied in the UKPDS study could add uncertainty to
the results provided by the outcome model. Based on
that, we re-ran the estimates in order to measure the
magnitude of the ethnicity effect among the options
provided by the simulation model. As shown in table 3,
Asian ethnicity renders a slightly higher mean 20 years
probability for having ischemic heart disease, myocardial
infarction and death compared to the Caucasian back-
ground. However, none of these differences reached sta-
tistical significance. The differences are significantly
greater when compared against the Afro-Caribbean heri-
tage. However, African heritage is very small (< 5%) in
the Mexicans [19]. Thus, the Afro-Caribbean ethnicity is
not a valid option for our study sample. In summary,
the selection of the Asian Indians as the group most
closely related to our study population may have minor
consequences on the estimates provided by the UKPDS
outcomes model.
Death and life expectancy
The model estimated that 539 (CI95% 508-570) per 1000
diabetic persons will have died within 20 years. In 2005,
the Mexican National Statistics and Geography Institute
(INEGI) estimated an average life expectancy of 74.6
years in the general population [20]. For individuals with
diabetes, the UKPDS model predicts an average life
expectancy (LE) of 10.9 years (95%CI 10.7-11.2); this
decreases to 8.3 years (95%CI 8.1-8.5) when QALY are
considered. Hence the average life expectancy for persons
with diabetes is 62.9 years. On adjustment for quality of
life, this figure is reduced to 60.3 years (see table 4).
Finally, when analyzing for gender, disease duration
and age at diagnosis, men older than 40 years at the
time of diagnosis and men with more than 10 years of
diabetes are expected to have a higher incidence of
complications (table 5). The life expectancy was greater
for women (11.1 years, 95% CI 10.8-11.4) compared to
men (10.7 years, 95% CI 10.5-11). The same was true
for patients aged 40 or younger (12.8 years, 95% CI
12.6-13.0) compared to older subjects (10.1 years, 95%
CI 9.8-10.3).
Discussion
The results of three population-based nationwide sur-
veys have shown that the prevalence of type 2 diabetes
has grown rapidly in México over the past few decades.
More than seven million Mexican adults now live with
diabetes. This report clearly shows that the burden
imposed by diabetes to Mexico will be very high risk
over the next twenty years. This report makes emphasis
in macrovascular complications, the main cause of death
among patients with type 2 diabetes [21]. The UKPDS
outcome model estimates that 53.9% (95 CI% 50.8-57%)
of currently affected subjects will be dead by the year
2026. Their life expectancy will be reduced to an aver-
age of 10.9 years (IC95% 10.7-11.2). The predicted 20
year-incidence of the principal cardiovascular complica-
tions per 1000 diabetic individuals are: ischemic heart
disease 112, myocardial infarction 260, heart failure 113,
stroke 101 and amputation 62. These predictions must
urge the Mexican health system to establish effective
treatment programs and improve diabetes care. In the
absence of such measures, the resources required to
manage future diabetes related complications will sur-
pass the capability of the Mexican health system.
Strengths of the study and implications for the Mexican
Health system
Simulation modeling is gaining acceptance as a valu-
able tool for providing long-term prognostic informa-
tion [22]. Such data is often unavailable from clinical
or epidemiological studies. Its use has been incorpo-
rated in the analyses of several multicenter trials [23]
and cost effectiveness studies [24]. The validity of the
estimates depends on the model’sa s s u m p t i o n sa n do n
the quality of data selected as inputs for the program.
The UKPDS outcomes model is one of the more
accepted simulation models, because it is based on
prospectively registered data [13]. This risk engine per-
forms better than the Framingham equation for the
prediction of coronary heart disease rates [25]. With
regards to the quality of data, we have used the best
possible source of information to make our estimates.
D a t aw a so b t a i n e df r o map o p u l a t i o nb a s e d ,n a t i o n -
wide survey and collected using a probabilistic, multi-
staged, stratified sampling method. This guarantees
national, regional and urban/rural representation.
Trained personnel obtained information using standar-
dized methodologies. Also, estimates were done for
Table 3 Twenty year accumulated probability for having
macrovascular complications or death: effect of ethnicity
Outcome Asian White Afro-Caribbean
Ischemic heart disease 0.112
(0.084-0.14)
0.090
(0.064-0.117)
0.096
(0.068-0.124)
Myocardial infarction 0.259
(0.215-0.304)
0.220
(0.174-0.265)
0.075*
(0.015-0.134)
Heart failure 0.112
(0.065-0.161)
0.115
(0.067-0.163)
0.124
(0.072-0.175)
Cerebrovascular disease 0.101
(0.069-0.133)
0.096
(0.067-0.125)
0.110
(0.080-0.140)
Amputation 0.062
(0.040-0.085)
0.063
(0.040-0.086)
0.068
(0.043-0.093)
Death 0.538
(0.508-0.570)
0.529
(0.495-0.563)
0.489
(0.455-0.524)
Data are presented as means (95% confidence intervals)
* p < 0.001 AfroCaribbean versus Asian or White.
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In countries, like México, in which diabetes is highly
prevalent, the onset of the disease happens at earlier
ages [26]. This feature boosts the adverse conse-
quences of diabetes [27]. The longer exposure to
hyperglycemia and other diabetes-related abnormalities
increase the likelihood that patients will develop
chronic complications. Thus, our data provides a
panorama of possible scenarios regarding the incidence
of diabetic complications that Mexico may face in the
near future. Even if we consider only the most conser-
vative estimates, the future looks bleak (figure 1).
Table 4 Expected mortality in persons with diabetes in Mexico
Simulated years Accumulated
probability
Number of expected cases/1000 persons
with diabetes
95% Confidence
Interval
Total expected cases
(95% CI)
1 0.043 43 33 54 345,066
(263,705-426,428)
5 0.162 162 144 180 1,280,852
(1,138,935-1,422,769)
10 0.292 292 272 312 2,305,420
(2,148,055-2,462,786)
15 0.416 416 394 440 3,290,559
(3,111,409-3,469,410)
20 0.538 538 508 570 4,251,383
(4,007,547-4,495,220)
Table 5 Expected twenty years incidence of cardiovascular complications and life expectancy by gender, time of
evolution and age of diagnosis
Complication Probability
(95% CI)
Expected Cases
(95% CI)
Probability
(95% CI)
Expected Cases
(95% CI)
Probability
(CI95%)
Expected Cases*
(CI95%)
Women
n = 3,931,127
Time evolution
≤ 10 years
n = 6,652,964
Age at diagnosis
≤ 40 years
n = 2,590,066
Ischemic heart 0.095
(0.066-0.124)
373,457
(259,454-487,460)
0.117
(0.089-0.145)
778,397
(592,114-964,680)
0.087
(0.060-0.115)
225,336
(155,404-297,858)
Myocardial
infarction
0.196
(0.142-0.249)
770,501
(558,220-978,851)
0.264
(0.223-0.305)
1,756,382
(1,483,611-2,029,154)
0.129
(0.096-0.162)
334,119
(248,646-419,591)
Heart failure 0.127
(0.072-0.183)
499,253
(283,041-719,396)
0.107
(0.065-0.148)
711,867
(432,443-984,639)
0.037
(0.016-0.058)
95,832
(41,441-150,224)
Cerebrovascular
disease
0.093
(0.063-0.122)
365,595
(247,661-479,597)
0.097
(0.068-0.126)
645,338
(452,402-838,273)
0.030
(0.003-0.057)
77,702
(7,770-147,634)
Amputation 0.065
(0.040-0.089)
255,523
(157,245-349,870)
0.058
(0.040-0.077)
385,872
(266,119-512,278)
0.065
(0.036-0.094)
168,354
(93,242-243,466)
Death 0.531
(0.498-0.565)
2,087,428
(1,957,701-2,221,087)
0.467
(0.435-0.499)
3,106,934
(2,894,039-3,319,829)
0.283
(0.250-0.317)
7,332,989
(647,517-821,051)
Men
n = 3,961,850
Time evolution
> 10 years
n = 1,240,012
Age at diagnosis
> 40 years
n = 5,302,911
Ischemic heart
disease
0.136
(0.102-0.170)
538,812
(404,109-673,515)
0.080
(0.050-0.110)
99,201
(62,001-136,401)
0.122
(0.091-0.152)
646,955
(482,565-806,042)
Myocardial
infarction
0.352
(0.315-0.390)
1,394,571
(1,247,983-1,545,122)
0.231
(0.161-0.301)
286,443
(199,642-372,244)
0.315
(0.260-0.370)
1,670,417
(1,378,757-1,962,077)
Heart failure 0.091
(0.053-0.128)
360,528
(209,978-507,117)
0.148
(0.056-0.241)
183,522
(69,441-298,843)
0.145
(0.085-0.204)
768,922
(450,747-1,081,794)
Cerebrovascular
disease
0.112
(0.074-0.149)
443,727
(293,177-590,316)
0.120
(0.065-0.175)
148,801
(80,601-217,002)
0.131
(0.094-0.168)
694,681
(498,474-890,889)
Amputation 0.059
(0.039-0.079)
233,749
(154,512-312,986)
0.088
(0.037-0.139)
109,121
(45,880-172,362)
0.062
(0.041-0.082)
328,780
(217,419-434,839)
Death 0.550
(0.522-0.578)
2,179,018
(2,068,086-2,289,949)
0.956
(0.928-0.984)
1,185,451
(1,150,731-1,220,172)
0.647
(0.612-0.681)
3,430,983
(3,245,382-3,611,282)
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required to validate the precision of the estimates
reported here.
Limitations of the study
The main disadvantage of simulation models is that esti-
mates are not precise for persons who have characteris-
tics different to that of persons who participated in the
original trial. Latino populations, for example, were not
included in the UKPDS. Despite this concern, the
UKPDS outcome model has been applied in multiethnic
study samples [28,29]. To counter this factor, we treated
our study sample as Asian Indians, which is an ethnic
group included in the UKPDS study that shares biologi-
cal and socio-economical characteristics with Latin
populations [17,18]. We re-ran the estimates in order to
measure the magnitude of the ethnicity effect among
the options provided by the simulation model. Minor,
non significant differences were found if an Asian or a
Caucasian background was assumed in the modeling
process. Thus, the selectiono ft h eA s i a nI n d i a n sa st h e
group most closely related to our study population may
have minor consequences on the estimates reported
here. In addition, we validated the prognostic value for
CVD events of the UKPDS outcome model in a group
of Mexican patients followed up for over ten years. The
discrimination (c = 0.66 (IC 95% 0.59-0.72) for CVD
events reported here is similar to that reported in the
multiethnic ADVANCE study (c = 0.70 (0.65-0.76)) [28]
and in a cohort composed of Caucasians (c = 0.670)
[14]. This observation suggests that the UKPDS out-
come model estimates may be as valid in Mexicans as in
other ethnic groups. Other limitations may affect our
ability to predict the CVD outcomes. The UKPDS out-
come model measures the probability of presenting the
first event, but not subsequent ones. For instance, it
does not consider the existence of a double amputation.
Also, the model simulates the progression of diabetes
under “conventional treatment” within the UKPDS
study. Conventional treatment in Mexico is much more
varied. In addition, the UKPDS risk engines apply to
people with newly diagnosed diabetes. Here, the model
was applied to both undiagnosed and diagnosed cases of
diabetes. Finally, the estimates are derived from a single
measurement. Despite these limitations, the value of the
present analysis depends largely on the extent to which
the participants of the Encuesta Nacional de Salud y
Nutricion are representative of current populations of
patients with type 2 diabetes living in México.
The UPKDS outcome model is thought to either over-
estimate [24] or underestimate CVD risk [14] depending
on the nature of the population under study. It is prob-
able that the model may overestimate the CVD risk in a
population-based sample [30] like the one reported
ϮϬϬϲ ϭϵϵϯ ϮϬϮϲ ϮϬϭϲ
zĞĂƌ
WƌĞǀĂůĞŶĐĞŝŶĂĚƵůƚƐ ϲ͘ϳй ϭϰ͘ϰй
EƵŵďĞƌŽĨĐĂƐĞƐ
;ŵŝůůŝŽŶƐͿ
ϯ͘Ϭ ϳ͘ϭ
WĞƌĐĞŶƚĂŐĞŽĨƚŚĞĞǆŝƐƚŝŶŐĐĂƐĞƐŝŶϮϬϬϲƚŚĂƚǁŝůůŚĂǀĞĂŶǇŽĨƚŚĞƐĞŽƵƚĐŽŵĞƐ͗
DǇŽĐĂƌĚŝĂůŝŶĨĂƌĐƚŝŽŶ ϭϱ͘ϵй Ϯϱ͘ϵй
,ĞĂƌƚĨĂŝůƵƌĞ ϲ͘ϵй ϭϭ͘Ϯй
ĞƌĞďƌŽǀĂƐĐƵůĂƌĚŝƐĞĂƐĞ ϲ͘ϯй ϭϬ͘ϭй
ŵƉƵƚĂƚŝŽŶ ϯ͘ϲй ϲ͘Ϯй
ĞĂƚŚ Ϯϵ͘Ϯй ϱϯ͘ϴй
Figure 1 Current and future burden imposed by type 2 diabetes in Mexico.
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Page 7 of 9here. Our CVD estimates are similar to those reported
in Mexican-Americans from the 1999-2002 National
Health and Nutrition Examination Survey [29]. The 10
year risk of CVD events (ischemic heart disease plus
myocardial infarction) estimated in our sample (22.8%)
was almost identical (22.5%) to that found in the Mexi-
can Americans.
Conclusions
The impact of type 2 diabetes on the Mexican health sys-
tem will be significantly greater in the next two decades.
Simulation modeling shows that if the clinical character-
istics of the diabetic population remain unaltered, a large
proportion of the diabetic population will suffer prema-
ture mortality and disabilities in the coming years.
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